Format

Send to

Choose Destination
See comment in PubMed Commons below
Lancet Oncol. 2015 Mar;16(3):312-9. doi: 10.1016/S1470-2045(15)70031-8. Epub 2015 Feb 11.

Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

Author information

1
Medical Oncology Department, Gustave Roussy, Villejuif, France.
2
Medical Oncology Department, Centre Léon Bérard and Claude Bernard University, Lyon, France.
3
Biostatistics Unit, Centre Oscar Lambret, Lille, France.
4
Medical Oncology Department, Institut Claudius Regaud, Toulouse, France.
5
Medical Oncology Department, Institut Paoli Calmette, Marseille, France.
6
Medical Oncology Department, Centre François Baclesse, Caen, Lille.
7
Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.
8
Medical Oncology Department, Insitut Curie, Paris, France.
9
Medical Oncology Department, Centre Oscar Lambret, Lille, France.
10
Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France.
11
Medical Oncology Department, Institut Bergonié, Bordeaux, France.
12
Clinical Research Unit, Centre Oscar Lambret, Lille, France; Methodology and Clinical Research Platform of SIRIC OncoLille, Lille, France.
13
Medical Oncology Department, Centre Oscar Lambret, Lille, France; Methodology and Clinical Research Platform of SIRIC OncoLille, Lille, France. Electronic address: n-penel@o-lambret.fr.

Abstract

BACKGROUND:

The benefit or harm of trabectedin discontinuation in patients with non-progressive soft-tissue sarcoma remains unclear. We report the final analysis of a phase 2 trial investigating the clinical benefit of continuation of trabectedin treatment until progression versus interruption of therapy after six treatment cycles in patients with advanced soft-tissue sarcoma.

METHODS:

For this open-label, non-comparative, multicentre, phase 2 study, eligible adult patients with advanced soft-tissue sarcomas, who had previously received doxorubicin-based chemotherapy and were able to receive trabectedin, were enrolled from 14 centres of the French Sarcoma Group. Trabectedin was administered at a dose of 1·5 mg/m(2) through a central venous line as a 24-h continuous infusion every 3 weeks. After the initial six cycles of trabectedin, patients who were free from progressive disease were randomly assigned in a 1:1 ratio either to continuous treatment or therapy interruption. Randomisation was done centrally by a computer-generated system using permuted blocks of four patients, stratified by tumour grade and performance status. Patients allocated to the interruption group were allowed to restart trabectedin in case of progressive disease. The primary endpoint was progression-free survival at 6 months after randomisation, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01303094.

RESULTS:

In 178 evaluable patients, 91 (51%) patients had not progressed after six cycles. Of these patients, 53 patients were randomly assigned to the two treatment groups: 27 to the continuation group and 26 to the interruption group. Overall, patients in the two groups received a similar median number of trabectedin cycles (continuation group: 11 cycles [range 6-31+] vs interruption group: 11 [range 6-23+]). After randomisation, progression-free survival at 6 months was 51·9% (95% CI 31·9-68·6) in the continuation group versus 23·1% (9·4-40·3) in the interruption group (p=0·0200). The occurrence of treatment-related grade 3 adverse events (four [16%] of 25 patients in the continuation group vs three [14%] of 21 in the interruption group) and grade 4 adverse events (one [4%] vs none) was similar in both groups. The most common grade 3 and 4 toxicities were alanine aminotransferase or aspartate aminotransferase increases (one [4%] in the interruption group vs three [14%] in the continuation group), neutropenia (two [8%] vs two [10%]), and intestinal occlusion (one [4%] vs one [5%]).

INTERPRETATION:

We do not recommend trabectedin discontinuation in patients with advanced, doxorubicin-refractory soft-tissue sarcoma who have not progressed after six cycles of treatment.

FUNDING:

The French National Cancer Institute (INCa) and PharmaMar SA.

PMID:
25680558
DOI:
10.1016/S1470-2045(15)70031-8
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center